The small-molecular inhibitors targeted JAks (JAK inhibitors) could modulate the cytokines-mediated signaling via the JAK-STAT pathway, which plays an important role in immune regulation and cell proliferation. The JAK inhibitors were previously designed and synthesized to treat diseases involving the hematologic and immune system. Increasing evidence shows that they are quite effective in atopic dermatitis (AD), alopecia areata (AA), psoriasis, vitiligo, and other autoimmuneinduced dermatologic conditions. Currently, many JAK inhibitors possessing anti-vitiligo activity are being investigated in the laboratory and clinically. In this view, we would like to summarize the applications of these inhibitors with emphasis on the profile of vitiligo, clinical efficacy, dosages, development of new candidates and adverse events through available literature.